Back to News
Market Impact: 0.2
Leerink Partners Initiates Coverage of Obsidian Therapeutics with Outperform Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Leerink Partners initiated coverage of Obsidian Therapeutics (NASDAQCM: OBX) on September 22, 2026, with an Outperform recommendation. The initiation is a positive external endorsement for the biotech company, though the article provides no price target, earnings estimates, or fundamental details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- Axon Enterprise earnings analysis: questions answered and next catalysts
- Cvs Health evp Prem Shah buys $2 million in company stock
- Apollo-backed dental firm vVardis seeks up to $229 million in US IPO
- Truist cuts Construction Partners stock price target on diesel costs
- Freedom Broker raises Allison Transmission stock price target on strong Q3 results